Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 10/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 10/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 5/20 | 0.36 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 9/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298623 | 0.84 | NISCH (0.41) | ADRA2BADRA2CNISCHMAOAMAOB | |
| Hydrochloric Acid SCHEMBL7135197 | 0.82 | NISCH (0.41) | ADRA2BADRA2CNISCHMAOAMAOB | |
| SCHEMBL3264669 | 0.79 | — | — | |
| SCHEMBL1326510 | 0.78 | ADRA2B (0.38) | ADRA2BADRA2CNISCHMAOAMAOB | |
| SCHEMBL4912194 | 0.76 | ADRA2B (0.43) | ADRA2BADRA2CNISCHMAOAMAOB | |
| SCHEMBL11668041 | 0.72 | NOS3 (0.38) | ADRA2BADRA2CNISCHADRA2A | |
| SCHEMBL9754198 | 0.72 | ADRA2B (0.38) | ADRA2BADRA2CNISCHMAOAMAOB | |
| Sulfuric Acid SCHEMBL18045136 | 0.71 | RAD52 (0.35) | ADRA2BADRA2CNISCHMAOAMAOB | |
| SCHEMBL1768228 | 0.71 | — | — | |
| SCHEMBL7170244 | 0.69 | ADRA2B (0.35) | ADRA2BADRA2CNISCHMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023785-B2 | Gemini surfactants, process of manufacture and use as multifunctional corrosion inhibitors | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2015-05-05 | — | — | US | disclosed |
| US-20130340326-A1 | Gemini surfactants, process of manufacture and use as multifunctional corrosion inhibitors | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2013-12-26 | — | — | US | disclosed |
| US-8518868-B2 | Gemini surfactants, process of manufacture and use as multifunctional corrosion inhibitors | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2013-08-27 | — | — | US | disclosed |
| US-20110138683-A1 | Gemini surfactants, process of manufacture and use as multifunctional corrosion inhibitors | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110138683-A1 | Gemini surfactants, process of manufacture and use as multifunctional corrosion inhibitors | SCO2, F12, GLRB | ADRA2B 772/4885ADRA2C 1493/4885NISCH 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.